Migard (Frovatriptan)

Frovatriptan is a selective agonist of serotonin 5‑HT1B and 5‑HT1D receptors. By stimulating these receptors, it causes constriction of dilated cranial blood vessels and blocks the release of pain‑triggering neuropeptides from trigeminal nerves, thereby reducing migraine pain and associated symptoms.

The prescribed dose of Migard is determined by the treating physician based on the individual’s clinical condition, age, and response to therapy. Patients should follow the prescriber’s instructions and not exceed the recommended amount without medical advice.

Safety of Frovatriptan in pregnancy has not been established, and it is generally avoided unless the potential benefit outweighs the risk. Limited data are available for breastfeeding; therefore, use should be discussed with a healthcare professional to assess possible infant exposure.

To request Migard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Migard (Frovatriptan) belongs to the triptan class, which is generally more effective for moderate to severe migraine than non‑specific analgesics such as NSAIDs. Compared with other triptans, Frovatriptan has a longer half‑life, offering sustained relief but may have a slower onset of action.

Migard should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat, and direct sunlight to maintain stability and potency throughout the shelf life.

Migard is taken orally, usually as a single tablet at the first sign of a migraine attack. The tablet should be swallowed whole with water and not crushed or chewed. If the migraine recurs, a second dose may be taken after a minimum interval as advised by the prescriber.

Serious risks include coronary vasospasm, myocardial infarction, severe hypertension, and serotonin syndrome, especially when combined with other serotonergic drugs. Patients experiencing chest pain, severe headache, or signs of serotonin excess should seek immediate medical attention.

Migard is contraindicated in patients with known cardiovascular disease, uncontrolled hypertension, a history of stroke or transient ischemic attack, severe hepatic impairment, and those taking MAO inhibitors or other triptans. Individuals with known hypersensitivity to Frovatriptan or any excipients should also avoid its use.